Home > Cardiology > HFA 2022 > EMPEROR-Preserved: Empagliflozin stable across age groups

EMPEROR-Preserved: Empagliflozin stable across age groups

Presented By
Prof. Michael Böhm, University of the Saarland, Germany
HFA 2022
Data from the EMPEROR-Preserved trial showed that empagliflozin had a favourable effect on major cardiovascular outcomes and worsening of renal dysfunction irrespective of the age of patients with heart failure and preserved ejection fraction (HFpEF). Furthermore, the safety profile of empagliflozin in the elder population did not reveal clinically relevant issues [1]. The sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin has been shown safe and efficacious in patients with HFpEF in the EMPEROR-Preserved trial (NCT03057951) [2]. The current analysis, presented by Prof. Michael Böhm (University of the Saarland, Germany), investigated the efficacy of empagliflozin in the study population of this trial according to age. The EMPEROR-Preserved trial randomised 5,988 patients with HF and an ejection fraction of ≥40% to either placebo or empagliflozin. The pr...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on